3.585

4.52% 0.155

After Hours: 3.52 -0.065 -1.81%

Lenz Therapeutics Inc (LENZ)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Lenz Therapeutics Inc stock is traded at $3.585, with a volume of 722.63K. It is up +4.52% in the last 24 hours and down -15.25% over the past month. LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Previous Close:

$3.43

Open:

$3.43

24h Volume:

722.63K

Relative Volume:

0.93

Market Cap:

$112.64M

Revenue:

$19.09M

Net Income/Loss:

$-82.13M

P/E Ratio:

-1.2792

EPS:

-2.8026

Net Cash Flow:

$-70.00M

1W Performance:

+1.56%

1M Performance:

-15.25%

6M Performance:

-62.58%

1Y Performance:

-91.43%

1-Day Range:

$3.43

$3.64

1-Week Range:

$3.345

$3.71

52-Week Range:

$3.345

$42.98

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name

Lenz Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

858-925-7000

Address

201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH

Employee

152

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

LENZ's Discussions on Twitter

Compare LENZ vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LENZ Lenz Therapeutics Inc	3.585	112.64M	19.09M	-82.13M	-70.00M	-2.8026
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-12-26	Downgrade	Piper Sandler	Overweight → Neutral
Apr-14-25	Resumed	Piper Sandler	Overweight
Mar-18-25	Initiated	TD Cowen	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-12-24	Initiated	H.C. Wainwright	Buy
Apr-15-24	Initiated	Leerink Partners	Outperform
Apr-15-24	Initiated	William Blair	Outperform
Apr-10-24	Initiated	Citigroup	Buy
Mar-27-24	Initiated	Piper Sandler	Overweight
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-14-22	Initiated	BTIG Research	Buy
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform
Jul-20-21	Initiated	Morgan Stanley	Overweight
Jul-20-21	Initiated	SVB Leerink	Outperform

View All

Lenz Therapeutics Inc Stock (LENZ) Latest News

Oct 06, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - GlobeNewswire Inc.

Oct 06, 2026

Sep 11, 2026